{"meta":{"query_hash":"42b7d160b0d0","filters":{"venue":"Antibody Therapeutics"},"cohort_total":9,"direct_labels_cover":0,"predictions_cover":9,"exported":9,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/42b7d160b0d0","api":"https://metacan.xera.ac/api/v1/cohort?venue=Antibody+Therapeutics"},"results":[{"id":"W3183257671","doi":"10.1093/abt/tbab015","title":"SARS-CoV-2 receptor-binding mutations and antibody contact sites","year":2021,"lang":"en","type":"article","venue":"Antibody Therapeutics","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University of Toronto","keywords":"Antibody; Point mutation; Mutation; Immune escape; Infectivity; Biology; Virology; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Neutralization; Receptor; Binding site; Genetics; Coronavirus disease 2019 (COVID-19); Virus; Gene; Immune system; Medicine; Disease","score_opus":0.07671401143112645,"score_gpt":0.4119367174553563,"score_spread":0.3352227060242299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183257671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9429629,0.0018399818,0.002282971,0.00016145004,0.00003958496,0.000043700125,0.04942939,0.000446324,0.0027937144],"genre_scores_gemma":[0.8960956,0.0006673631,0.004683356,0.00014839055,0.000021792985,0.00005148145,0.09709841,0.00008077532,0.0011528296],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99960345,0.000045364788,0.000039228624,0.00014324719,0.00010364009,0.0000651191],"domain_scores_gemma":[0.99965847,0.000101965765,0.00012463464,0.000037105678,0.000045162196,0.000032649976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030563027,0.00037587172,0.0004416203,0.0010603918,0.00027912974,0.0004345458,0.0002564975,0.00030512922,0.0030372692],"category_scores_gemma":[0.00087791483,0.00010989249,0.000695962,0.0013599207,0.00014123684,0.0002731807,0.0002746845,0.0003063301,0.0010938639],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018160999,0.00034670046,0.78950304,0.0011753791,0.00063288753,0.0018099827,0.0002015036,0.01995527,0.08908763,0.0011483798,0.024003163,0.07031992],"study_design_scores_gemma":[0.00009599994,0.00047068292,0.87109715,0.00012487412,0.00037430524,0.0041520814,0.00034745128,0.04188738,0.025933772,0.0015799311,0.053875085,0.0000612427],"about_ca_topic_score_codex":0.0037926536,"about_ca_topic_score_gemma":0.0077033304,"teacher_disagreement_score":0.0037926536,"about_ca_system_score_codex":0.00024913653,"about_ca_system_score_gemma":0.0003870322,"threshold_uncertainty_score":0.010160685},"labels":[],"label_agreement":null},{"id":"W4205929832","doi":"10.1093/abt/tbab030","title":"CellCelector™ as a platform in isolating primary B cells for antibody discovery","year":2022,"lang":"en","type":"article","venue":"Antibody Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"Amgen","keywords":"Antibody; Antibody Repertoire; Biology; Recombinant DNA; B cell; Antigen; Immune system; Complementarity determining region; Computational biology; Immunoglobulin light chain; Immunology; Molecular biology; Gene; Genetics","score_opus":0.04107785918090384,"score_gpt":0.36492198671844694,"score_spread":0.3238441275375431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205929832","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20966077,0.006645439,0.758936,0.00077387394,0.00033127403,0.0015047085,0.00245912,0.0031937694,0.016495075],"genre_scores_gemma":[0.2732934,0.005561305,0.6909573,0.00068689854,0.00015364887,0.0018181985,0.0053035025,0.00049354986,0.021732224],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99944633,0.00011023682,0.000030511634,0.000112602895,0.00024319024,0.00005717975],"domain_scores_gemma":[0.99976736,0.00007219853,0.000038583035,0.000039825412,0.000044182925,0.000037745845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007856678,0.0006366701,0.00037790748,0.0006604541,0.00036381718,0.00064330566,0.00059121987,0.00052459136,0.0034771531],"category_scores_gemma":[0.0003365834,0.00046076858,0.00040191988,0.000336585,0.00029687953,0.00034202615,0.0006379371,0.001128426,0.0046803537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004570978,0.000029276585,0.00018412172,0.00007905297,0.0000080819245,0.00005561185,0.00002954754,0.00011483999,0.98986477,0.0005549604,0.00050428236,0.008529916],"study_design_scores_gemma":[0.000040332416,0.000368656,0.0014033384,0.00002975963,0.00003590179,0.00082445785,0.000022623508,0.0020550787,0.9465569,0.00042679164,0.048218228,0.000017988297],"about_ca_topic_score_codex":0.0003281804,"about_ca_topic_score_gemma":0.00073303195,"teacher_disagreement_score":0.0034771531,"about_ca_system_score_codex":0.00021374975,"about_ca_system_score_gemma":0.00040483678,"threshold_uncertainty_score":0.011632264},"labels":[],"label_agreement":null},{"id":"W4281629275","doi":"10.1093/abt/tbac013","title":"Intracellular flow cytometry staining of antibody-secreting cells using phycoerythrin-conjugated antibodies: pitfalls and solutions","year":2022,"lang":"en","type":"article","venue":"Antibody Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Stryker; Western Michigan University","keywords":"Phycoerythrin; Antibody; Intracellular; Biology; Flow cytometry; Molecular biology; Cell biology; Primary and secondary antibodies; Immunology; Chemistry","score_opus":0.05735818580034982,"score_gpt":0.35084410200562066,"score_spread":0.29348591620527087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281629275","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.079086296,0.017495401,0.8899729,0.0038387105,0.001287256,0.0006420705,0.0004135264,0.002078262,0.0051855342],"genre_scores_gemma":[0.25546086,0.01372322,0.7172194,0.0018871513,0.000448629,0.0025322316,0.0008414803,0.00041485607,0.0074722706],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99769175,0.00080661214,0.0002711086,0.0003510766,0.00071954116,0.00015996583],"domain_scores_gemma":[0.9977748,0.0010943351,0.0002772598,0.00035426847,0.0004073835,0.00009200911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004256169,0.001137644,0.0009165263,0.000888272,0.00074515503,0.0013204374,0.0012274875,0.0017911437,0.0024227973],"category_scores_gemma":[0.0022363914,0.0005544595,0.0005304837,0.0008176464,0.0015161047,0.0013718029,0.0008897624,0.0031395496,0.0014191105],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017750496,0.00009294941,0.0009826369,0.00093925465,0.000044785837,0.0002655079,0.0002675824,0.00042632443,0.9618418,0.00511118,0.002004608,0.027845804],"study_design_scores_gemma":[0.00003745157,0.0005220566,0.002218456,0.0002173323,0.00007343353,0.0018754478,0.00014130259,0.010731943,0.9389948,0.007969107,0.037162036,0.000056571756],"about_ca_topic_score_codex":0.0002018704,"about_ca_topic_score_gemma":0.0003344574,"teacher_disagreement_score":0.004256169,"about_ca_system_score_codex":0.0006543928,"about_ca_system_score_gemma":0.000599361,"threshold_uncertainty_score":0.022509098},"labels":[],"label_agreement":null},{"id":"W4387701119","doi":"10.1093/abt/tbad024","title":"<i>In vitro</i> generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2","year":2023,"lang":"en","type":"article","venue":"Antibody Therapeutics","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BrisSynBio; Engineering and Physical Sciences Research Council; Medical Research Council; Bundesministerium für Bildung und Forschung; Biotechnology and Biological Sciences Research Council; University of Bristol; Horizon 2020 Framework Programme; U.S. Food and Drug Administration; Max-Planck-Gesellschaft; Hamilton Health Sciences Foundation; European Research Council; British Society for Antimicrobial Chemotherapy; Wellcome Trust","keywords":"Virology; Immunization; Antibody; In vitro; Epitope; Vaccination; Chemistry; Biology; Computational biology; Immunology; Biochemistry","score_opus":0.06959123620409179,"score_gpt":0.3847022416211422,"score_spread":0.3151110054170504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387701119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8709891,0.0015530884,0.11346109,0.00035475005,0.000096947755,0.00020001085,0.00043560332,0.0004388975,0.012470518],"genre_scores_gemma":[0.9548054,0.00077885576,0.04014841,0.000121181605,0.000009020765,0.00008267517,0.00031414526,0.00005863129,0.0036816937],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991655,0.000014335542,0.0000056775943,0.000019086212,0.000027488864,0.000016772688],"domain_scores_gemma":[0.9999491,0.000007579023,0.000016585318,0.00000537407,0.000013811439,0.0000075663556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001889109,0.00035868806,0.00012041861,0.00009756894,0.00012144804,0.00037422383,0.00024531453,0.00024670683,0.0012896569],"category_scores_gemma":[0.00012273426,0.00014257901,0.00020064037,0.0000625199,0.00019061241,0.00019818306,0.00019729504,0.00029326853,0.000723829],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030006604,0.00002239319,0.00020703787,0.00005306909,0.0000040361147,0.000027053362,0.000015958653,0.0014685825,0.9940317,0.0008637062,0.00014812099,0.0031282662],"study_design_scores_gemma":[0.0000065564345,0.00016672774,0.00029469453,0.0000046245423,0.0000075280445,0.000059875507,0.000012858084,0.004801603,0.988918,0.00010280421,0.0056193713,0.00000520776],"about_ca_topic_score_codex":0.0004008456,"about_ca_topic_score_gemma":0.0006514101,"teacher_disagreement_score":0.0012896569,"about_ca_system_score_codex":0.00035415465,"about_ca_system_score_gemma":0.0002291029,"threshold_uncertainty_score":0.004314363},"labels":[],"label_agreement":null},{"id":"W4391055852","doi":"10.1093/abt/tbae002","title":"Effects of Fc glycosylation on the activity of WNT mimetic agonistic antibodies","year":2024,"lang":"en","type":"article","venue":"Antibody Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Wnt signaling pathway; Agonistic behaviour; Monoclonal antibody; Antibody; Epitope; Frizzled; Receptor; Glycosylation; Biology; Cell biology; Signal transduction; Immunology; Biochemistry; Medicine","score_opus":0.03437245680134031,"score_gpt":0.3579252745880478,"score_spread":0.32355281778670747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391055852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532616,0.0011676877,0.0015930608,0.00010063001,0.000027373631,0.000025852602,0.0000997895,0.000024308007,0.0016351483],"genre_scores_gemma":[0.9973514,0.00070182426,0.0011881212,0.00008643785,0.000008446931,0.000014484848,0.000102824924,0.000011448222,0.0005350105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996557,0.00010390035,0.000035098972,0.00003785294,0.00008046611,0.00008694415],"domain_scores_gemma":[0.9997373,0.00013444852,0.000045565295,0.000025162297,0.000036690235,0.000020774432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055678416,0.00032639128,0.00018581233,0.00011017138,0.00010491269,0.00020916291,0.00021095383,0.00021931906,0.0010332409],"category_scores_gemma":[0.0007135373,0.00011351091,0.00012865933,0.00016790007,0.00019295099,0.00017852239,0.00015192927,0.0003726983,0.00012926903],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030667303,0.000051792947,0.00021461255,0.000047201163,0.000009832179,0.000058753383,0.000029799112,0.00023589646,0.99609476,0.00015118379,0.00006791084,0.0027315111],"study_design_scores_gemma":[0.000013873825,0.00037537253,0.0010637203,0.0000038604303,0.000014491111,0.000071582064,0.00001118352,0.00059581257,0.9969152,0.000021220769,0.0009098747,0.00000376202],"about_ca_topic_score_codex":0.00094363955,"about_ca_topic_score_gemma":0.0008501865,"teacher_disagreement_score":0.0010332409,"about_ca_system_score_codex":0.00024761716,"about_ca_system_score_gemma":0.00014477331,"threshold_uncertainty_score":0.003456533},"labels":[],"label_agreement":null},{"id":"W4392201225","doi":"10.1093/abt/tbae006","title":"Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential","year":2024,"lang":"en","type":"article","venue":"Antibody Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Natural Sciences and Engineering Research Council of Canada","funders":"Nihon University","keywords":"Monoclonal antibody; Immunology; Medicine; Cancer; Antibody; Cancer research; Internal medicine","score_opus":0.04413262267728627,"score_gpt":0.3679099479761028,"score_spread":0.32377732529881653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392201225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9673884,0.007986908,0.01675462,0.00051807676,0.00019746278,0.0005592508,0.00047653678,0.0002813396,0.005837429],"genre_scores_gemma":[0.97459567,0.0041756597,0.014435697,0.00049333065,0.000073162344,0.00028176067,0.0016147452,0.000025234798,0.004304706],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998018,0.000036192116,0.000014160067,0.000034325014,0.000057390454,0.00005610251],"domain_scores_gemma":[0.99992526,0.000010665082,0.000012792059,0.000008652173,0.00001916141,0.000023472974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002615484,0.0005126181,0.00038937977,0.00037833877,0.0001358138,0.00029909064,0.00053806,0.0005416268,0.0015651031],"category_scores_gemma":[0.00017429386,0.00022620716,0.0003522421,0.00019087156,0.00016350101,0.0002647351,0.00021707264,0.0009073919,0.00057230843],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002447252,0.0004596328,0.00036400522,0.00010188315,0.000036790036,0.00012565493,0.00002036039,0.00048454045,0.9759261,0.00029694557,0.0005848256,0.02135448],"study_design_scores_gemma":[0.0008288218,0.00973233,0.0060277716,0.000031091062,0.00022831671,0.0024757609,0.000036007732,0.005869866,0.941884,0.00013538702,0.032722052,0.000028654418],"about_ca_topic_score_codex":0.00074839947,"about_ca_topic_score_gemma":0.0011039827,"teacher_disagreement_score":0.0015651031,"about_ca_system_score_codex":0.0003977559,"about_ca_system_score_gemma":0.00046446908,"threshold_uncertainty_score":0.005235791},"labels":[],"label_agreement":null},{"id":"W4405431764","doi":"10.1093/abt/tbae031","title":"Humanized anti-CD11d monoclonal antibodies suitable for basic research and therapeutic applications","year":2024,"lang":"en","type":"article","venue":"Antibody Therapeutics","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Robarts Research Institute; Canadian Institutes of Health Research; Eli Lilly and Company; U.S. Department of Defense","keywords":"Monoclonal antibody; Flow cytometry; Antibody; Biology; Humanized mouse; Humanized antibody; Immunology; Medicine; Cancer research; Immune system","score_opus":0.13005799972134577,"score_gpt":0.45340570663635865,"score_spread":0.3233477069150129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405431764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7336808,0.039289434,0.18940008,0.0019341296,0.00093620364,0.0021920982,0.002703757,0.0012820798,0.028581483],"genre_scores_gemma":[0.8385373,0.016269984,0.11700797,0.0011253579,0.00032601296,0.0019811674,0.00553769,0.00014325124,0.019071357],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99956375,0.000107440195,0.000049153554,0.000103890394,0.00009022298,0.00008554075],"domain_scores_gemma":[0.99977964,0.000042250278,0.000042183325,0.00004323168,0.000054539432,0.00003816915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005636882,0.0010770751,0.00032982713,0.00045201866,0.00018120701,0.0005816352,0.00044066258,0.0008173792,0.005555088],"category_scores_gemma":[0.0003781693,0.00032176552,0.000345204,0.00031014002,0.0002451485,0.00032220111,0.00031109506,0.0010496886,0.0015863464],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002020986,0.0001259716,0.00024513123,0.00014733149,0.000014620119,0.000072344716,0.000013082563,0.00015110798,0.9855054,0.00062635745,0.0006703973,0.012226308],"study_design_scores_gemma":[0.00025505488,0.0012110451,0.0029206388,0.000079069985,0.00008627454,0.0015634312,0.000019887093,0.0017792155,0.91423,0.00039052378,0.077443406,0.000021369968],"about_ca_topic_score_codex":0.00025314238,"about_ca_topic_score_gemma":0.0003963675,"teacher_disagreement_score":0.005555088,"about_ca_system_score_codex":0.00058994576,"about_ca_system_score_gemma":0.00044250733,"threshold_uncertainty_score":0.018583655},"labels":[],"label_agreement":null},{"id":"W4411732853","doi":"10.1093/abt/tbaf011","title":"Broadly reactive anti-VHH antibodies for characterizing, blocking, or activating nanobody-based CAR-T cells","year":2025,"lang":"en","type":"article","venue":"Antibody Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; National Research Council Canada; Institute of Infection and Immunity; University of Ottawa","funders":"National Research Council Canada","keywords":"Blocking (statistics); Antibody; Blocking antibody; Chemistry; Cell biology; Computer science; Biology; Immunology; Computer network","score_opus":0.05023550247450955,"score_gpt":0.3928942831989447,"score_spread":0.3426587807244352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411732853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8928453,0.0038194906,0.09565113,0.00026088566,0.00011642053,0.00034416976,0.0005494682,0.0005136945,0.0058993823],"genre_scores_gemma":[0.9585541,0.0013797444,0.03607121,0.00023441644,0.000050640978,0.00015717366,0.000795301,0.00007280411,0.0026845864],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995727,0.00007416555,0.00003013404,0.000108014225,0.00012650828,0.00008848494],"domain_scores_gemma":[0.9998122,0.00004151627,0.000046312805,0.00003165562,0.000040282182,0.000028044204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044101724,0.00068730663,0.00019127184,0.000440621,0.00012664957,0.00037416286,0.0004431792,0.00057936896,0.0015186968],"category_scores_gemma":[0.00022890639,0.00014991072,0.0003282793,0.00015826576,0.00027544767,0.00023635947,0.0003229703,0.0007119787,0.00061076955],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001788773,0.000031560066,0.00018360162,0.000039173963,0.0000058873725,0.00002598671,0.000009702176,0.000106371896,0.9972658,0.00018437507,0.000060353246,0.0020692528],"study_design_scores_gemma":[0.000011395704,0.00015952172,0.00055816513,0.000007287695,0.000022606315,0.0002564727,0.000007589764,0.0009758875,0.99436605,0.000058717458,0.0035729555,0.0000033829253],"about_ca_topic_score_codex":0.00016396736,"about_ca_topic_score_gemma":0.00032582946,"teacher_disagreement_score":0.0015186968,"about_ca_system_score_codex":0.0003951738,"about_ca_system_score_gemma":0.00019610372,"threshold_uncertainty_score":0.005080521},"labels":[],"label_agreement":null},{"id":"W4415765237","doi":"10.1093/abt/tbaf023","title":"The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity","year":2025,"lang":"en","type":"article","venue":"Antibody Therapeutics","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Cell; Cell growth; Cell culture; T cell; Immunotherapy; Gene","score_opus":0.028273091122312872,"score_gpt":0.3042693476961837,"score_spread":0.27599625657387084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415765237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9558457,0.002464762,0.03755756,0.0002771177,0.00012677758,0.00014670554,0.0003663739,0.00025182188,0.0029630656],"genre_scores_gemma":[0.9837302,0.0005177378,0.013382831,0.00014640659,0.0000141155115,0.00006028982,0.0003207028,0.000017795042,0.0018099855],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998518,0.000019914738,0.000018623115,0.000029298102,0.000043681033,0.00003672973],"domain_scores_gemma":[0.99992037,0.000009115544,0.00002334708,0.000013344925,0.000014129773,0.000019616984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019723127,0.0002435004,0.00018500934,0.00010457968,0.00005856674,0.00034168994,0.00029731318,0.00029099916,0.001181598],"category_scores_gemma":[0.00015333854,0.00007953288,0.00023794951,0.000073850046,0.00015342745,0.00031171762,0.0002826718,0.00056044816,0.0004288635],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010351193,0.00004153122,0.00023698546,0.00005156901,0.000009554787,0.00004483552,0.00001313232,0.00056267675,0.99427587,0.00035041937,0.00013261769,0.0041773613],"study_design_scores_gemma":[0.00002658459,0.00052264164,0.00039058205,0.000006047515,0.000017013488,0.00019054103,0.000009003392,0.0026032187,0.9919723,0.00007353714,0.0041830093,0.000005445985],"about_ca_topic_score_codex":0.0001453131,"about_ca_topic_score_gemma":0.00020632114,"teacher_disagreement_score":0.001181598,"about_ca_system_score_codex":0.00025809498,"about_ca_system_score_gemma":0.00016764922,"threshold_uncertainty_score":0.003952861},"labels":[],"label_agreement":null}]}